Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansa Biopharma AB ( (SE:HNSA) ) just unveiled an update.
Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will participate in two significant industry events: Optimum’s 17th Annual Healthcare Investor Conference and Nordic Life Science Days 2025. These engagements highlight Hansa’s active role in shaping industry discussions on exit strategies and future financing trends, potentially enhancing its visibility and influence in the biopharmaceutical sector.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 580,607
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.3B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.